Halozyme director receives RSU and option grants

HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program. He acquired 3,796 shares of common stock at no cash cost through a restricted stock unit grant.

He was also granted options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders. After these grants, he directly holds 14,462 shares of common stock.

Insider Trade Summary

Grant/Award: 9,836 shares

Grant/Award 2 txns

Insider Krishnan Mahesh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	6,040	$0.00	$0.00
Grant/Award	Common Stock	3,796	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 6,040 contracts (Direct); Common Stock — 14,462 shares (Direct)

Footnotes (2)

1. F1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.
2. F2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

RSU grant: 3,796 shares Option grant size: 6,040 options Option exercise price: $65.87 per share +4 more

7 metrics

RSU grant 3,796 shares Annual restricted stock unit grant to director

Option grant size 6,040 options Annual stock option grant to director

Option exercise price $65.87 per share Exercise price for 6,040 stock options

Shares after transaction 14,462 shares Common stock directly held after grants

Underlying option shares 6,040 shares Common shares underlying the option grant

Vesting date May 5, 2027 Latest vesting date for RSUs and options

Option expiration May 5, 2036 Expiration of stock option grant

Key Terms

restricted stock unit ("RSU"), director compensation program, stock option, vest in full

4 terms

restricted stock unit ("RSU") financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

director compensation program financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

stock option financial

"Represents annual stock option grant under the Issuer's director compensation program."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest in full financial

"This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Halozyme (HALO) director Mahesh Krishnan acquire in this Form 4 filing?

Halozyme director Mahesh Krishnan received equity awards, including 3,796 restricted stock units and options for 6,040 shares. These awards are part of the company’s director compensation program and provide future ownership and purchase rights in Halozyme common stock, subject to vesting conditions.

How many Halozyme (HALO) shares does Mahesh Krishnan hold after the reported transactions?

After the reported equity awards, Mahesh Krishnan directly holds 14,462 shares of Halozyme common stock. This total reflects the addition of 3,796 shares from the restricted stock unit grant, which represents stock-based compensation rather than an open-market purchase.

What are the key terms of the stock options granted to Halozyme (HALO) director Mahesh Krishnan?

Mahesh Krishnan was granted options to purchase 6,040 Halozyme common shares at an exercise price of $65.87 per share, expiring May 5, 2036. These options vest in full on the earlier of May 5, 2027 or the company’s next annual stockholder meeting.

When do the restricted stock units granted to Halozyme (HALO) director Mahesh Krishnan vest?

The 3,796 restricted stock units granted to Mahesh Krishnan vest in full on the earlier of May 5, 2027 or the date of Halozyme’s next annual meeting of stockholders. Upon vesting, each unit converts into one share of Halozyme common stock.

Are Mahesh Krishnan’s Halozyme (HALO) equity awards part of a standard director compensation program?

Yes. The filing states both the 3,796 restricted stock units and 6,040 stock options represent annual grants under Halozyme’s director compensation program. These awards follow a standard structure with full vesting at the earlier of a set date or the next annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 07:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishnan Mahesh

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		3,796(1)	A	$0	14,462	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$65.87	05/05/2026		A		6,040		(2)	05/05/2036	Common Stock	6,040	$0	6,040	D

Explanation of Responses:

1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)